Product Description
a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) for the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04782128)
Mechanisms of Action: VEGF Blocker, FGFR2 Blocker
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: RemeGen
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Macular Edema|Wet Macular Degeneration
Phase 2: Diabetic Retinopathy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20202586 |
CTR20202586 | P2 |
Completed |
Diabetic Retinopathy |
2024-07-05 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT05885503 |
28C005 | P3 |
Recruiting |
Macular Edema |
2026-06-01 |
11% |
2023-09-06 |
|
CTR20230065 |
CTR20230065 | P3 |
Completed |
Wet Macular Degeneration |
2025-11-13 |
2025-12-14 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20202526 |
CTR20202526 | P2 |
Completed |
Macular Edema |
2023-09-13 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04782115 |
28C002 | P2 |
Completed |
Macular Edema |
2023-07-31 |
52% |
2023-09-01 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |